Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05410002 · ClinicalTrials.gov registry record · Phase 1

Diet Effect on Cancer Treatment Outcome

A Phase 1 study, sponsored by Optimal Health Research.

Completed
Registry status
Phase 1
Development phase
160
Enrollment target

NCT05410002: Completed Phase 1 study, sponsored by Optimal Health Research.

NCT05410002 is a Phase 1 study that has completed, run by Optimal Health Research. The registered enrollment target is 160 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (167% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05410002, a Phase 1 study, has completed, sponsored by Optimal Health Research.

COMPLETED
Registry status
Phase 1
Development phase
160 participants
Enrollment target

Study Summary

The study will look at the end result of 2 types of diets effect on treatment outcome of cancer patients using N-111.

Primary Outcome

Change in blood levels (CA, CMP, CBC, CEA, Lipids, CRP) from base line to the end of month 3.

Interventions

  • OTHER Placebo
  • DIETARY_SUPPLEMENT Dietary Supplement: N-111

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2022-10-12
Est. Completion 2024-10-01
Phase Phase 1
Optimal Health Research

5 total trials

What the finished NCT05410002 record still lists

NCT05410002 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (167% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT05410002 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05410002 about?

NCT05410002 is a clinical study titled "Diet Effect on Cancer Treatment Outcome". The study will look at the end result of 2 types of diets effect on treatment outcome of cancer patients using N-111.

What is the current status of trial NCT05410002?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2022-10-12. Estimated completion is 2024-10-01.

What interventions are being tested in trial NCT05410002?

The interventions under investigation include: Placebo (OTHER), Dietary Supplement: N-111 (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05410002?

This trial is sponsored by Optimal Health Research, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05410002's enrollment target sits among peer trials

160 340th of 2000 higher than 1,655 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00501826 · 160 participants · Phase 2

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • NCT00932139 · 160 participants · NA

    Effect of Electro-Acupuncture on Blood Pressure

  • NCT00992901 · 160 participants · Early Phase 1

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

  • NCT01515527 · 160 participants · Phase 2

    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05410002, the US trial registry maintained by the National Library of Medicine. NCT05410002 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.